{"id":"warfarin-or-coumadin","safety":{"commonSideEffects":[{"rate":"1-3% major bleeding annually","effect":"Bleeding (major and minor)"},{"rate":"<1%","effect":"Warfarin-induced skin necrosis"},{"rate":"rare","effect":"Alopecia"},{"rate":"1-2%","effect":"Nausea"},{"rate":"1-2%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin acts as a vitamin K antagonist, interfering with the gamma-carboxylation of clotting factors II, VII, IX, and X in the liver. This prevents these factors from becoming fully activated and functional in the coagulation cascade. The result is a prolonged prothrombin time (PT/INR) and reduced thrombin generation, which decreases the risk of thrombotic events.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the regeneration of reduced vitamin K, thereby reducing the formation of blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:59.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT07441382","phase":"NA","title":"Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Atrial Fibrillation (AF), Stroke, Hemorrhage","enrollment":200},{"nctId":"NCT07246005","phase":"PHASE2","title":"LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-12-01","conditions":"Left Ventricular Thrombus","enrollment":120},{"nctId":"NCT07434661","phase":"PHASE3","title":"Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","status":"NOT_YET_RECRUITING","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2026-02","conditions":"Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery","enrollment":120},{"nctId":"NCT07404436","phase":"PHASE4","title":"Rivaroxaban in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-05","conditions":"Idiopathic Membranous Nephropathy","enrollment":134},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT07349875","phase":"PHASE4","title":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-01","conditions":"Coronary Artery Disease (CAD)","enrollment":3826},{"nctId":"NCT07330869","phase":"","title":"Warfarin Effects on Male Fertility After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Città di Lecce Hospital, GVM Care & Research","startDate":"2026-02","conditions":"Male Infertility, Heart Valve Disease","enrollment":90},{"nctId":"NCT04045093","phase":"PHASE4","title":"Dabigatran for Mitral Stenosis Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-10-22","conditions":"Atrial Fibrillation, Mitral Stenosis","enrollment":370},{"nctId":"NCT07128888","phase":"PHASE1","title":"Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-11-17","conditions":"Obesity or Overweight","enrollment":60},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT07068841","phase":"PHASE1","title":"Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-05-18","conditions":"Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction","enrollment":24},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT05782270","phase":"PHASE4","title":"Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-11","conditions":"Anticoagulation, Coronary Endarterectomy","enrollment":202},{"nctId":"NCT06975605","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","status":"COMPLETED","sponsor":"GRIN Therapeutics, Inc.","startDate":"2025-05-20","conditions":"Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders","enrollment":18},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT07208695","phase":"","title":"Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2025-10-01","conditions":"Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins","enrollment":40},{"nctId":"NCT03225820","phase":"","title":"Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2017-11-09","conditions":"Information Seeking Behavior","enrollment":1000},{"nctId":"NCT06920056","phase":"PHASE1","title":"A Study of BGM0504 in Overweight or Obese Participants","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2025-03-24","conditions":"Overweight or Obese","enrollment":28},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT07081035","phase":"PHASE4","title":"Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-10","conditions":"Advanced Heart Failure, Left Ventricular Assist Devices, Anticoagulation Treatment","enrollment":94},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT02318342","phase":"NA","title":"Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2014-12","conditions":"Prosthetic Valve Thrombosis","enrollment":3000},{"nctId":"NCT06789588","phase":"PHASE3","title":"Protocol for Improvement of Therapy With Warfarin","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pernambuco","startDate":"2024-10-21","conditions":"Atrial Fibrillation (AF)","enrollment":700},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06289504","phase":"PHASE1","title":"A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Obesity","enrollment":34},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06844227","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2021-12-01","conditions":"Atrial Fibrillation (AF)","enrollment":1780},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT06402851","phase":"PHASE4","title":"Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)","status":"RECRUITING","sponsor":"Hospital Sirio-Libanes","startDate":"2024-12-18","conditions":"Atrium; Fibrillation, Chronic Kidney Diseases","enrollment":1500},{"nctId":"NCT04250116","phase":"PHASE4","title":"Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2020-04-28","conditions":"Atrial Fibrillation","enrollment":960},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT00291525","phase":"NA","title":"Randomized On-X Anticoagulation Trial","status":"COMPLETED","sponsor":"On-X Life Technologies, Inc.","startDate":"2006-06-06","conditions":"Heart Valve Disease","enrollment":977},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT03512080","phase":"","title":"Warfarin Anticoagulation in Patients in Sub-Saharan Africa","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-06-11","conditions":"Cardiovascular Diseases","enrollment":681},{"nctId":"NCT02376010","phase":"PHASE4","title":"Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2015-04-02","conditions":"Atherosclerosis","enrollment":110},{"nctId":"NCT02677974","phase":"","title":"On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"On-X Life Technologies, Inc.","startDate":"2015-11-10","conditions":"Thrombotic and Bleeding Events","enrollment":510},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT05824923","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure","status":"RECRUITING","sponsor":"Pulnovo Medical (Wuxi) Co., Ltd.","startDate":"2023-08-14","conditions":"Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension","enrollment":264},{"nctId":"NCT03596502","phase":"","title":"Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-02-01","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":402764},{"nctId":"NCT05419583","phase":"NA","title":"Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-11-14","conditions":"Myocardial Infarction Type 2","enrollment":60},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT04254783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-27","conditions":"Ulcerative Colitis (UC), Crohn's Disease","enrollment":20},{"nctId":"NCT06476301","phase":"PHASE4","title":"Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Anticoagulation","enrollment":250},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT06401616","phase":"PHASE4","title":"Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-05-21","conditions":"Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction","enrollment":1220},{"nctId":"NCT05204212","phase":"NA","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","status":"RECRUITING","sponsor":"Prof. Dr. med. Ingo Eitel","startDate":"2022-03-28","conditions":"Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent","enrollment":430},{"nctId":"NCT04887194","phase":"PHASE1","title":"PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-04-08","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT05563714","phase":"NA","title":"Anticoagulation With Enhanced Gastrointestinal Safety","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-10-05","conditions":"Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding","enrollment":341},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT05006287","phase":"PHASE2","title":"The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","startDate":"2022-10-12","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT04142658","phase":"PHASE3","title":"PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban","status":"TERMINATED","sponsor":"Artivion Inc.","startDate":"2020-05-01","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure","enrollment":863},{"nctId":"NCT05051904","phase":"","title":"A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-05-17","conditions":"Coronary Artery Disease, Atrial Fibrillation","enrollment":39357},{"nctId":"NCT06269302","phase":"","title":"Comparison of the Effect of Warfarin and Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Samsun Education and Research Hospital","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Gastrointestinal Hemorrhage","enrollment":346},{"nctId":"NCT04662515","phase":"","title":"NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications","status":"COMPLETED","sponsor":"Malmö University","startDate":"2016-06-01","conditions":"Surgery, Oral, Hemorrhage, Postoperative Complications","enrollment":216},{"nctId":"NCT05321810","phase":"","title":"Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-15","conditions":"Non-valvular Atrial Fibrillation","enrollment":193565},{"nctId":"NCT03684564","phase":"PHASE2","title":"RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke","enrollment":43},{"nctId":"NCT06145269","phase":"EARLY_PHASE1","title":"Recanalization Rate of Acute DVT","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"Acute DVT of Lower Extremity","enrollment":100},{"nctId":"NCT05815680","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-04-06","conditions":"Overweight Subjects, Obese Subjects","enrollment":48},{"nctId":"NCT04730037","phase":"PHASE3","title":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2021-03-23","conditions":"CTEPH","enrollment":74},{"nctId":"NCT03757481","phase":"NA","title":"Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2018-01-01","conditions":"Post Thrombotic Syndrome, Deep Vein Thrombosis, Chronic Thromboembolic Pulmonary Hypertension","enrollment":156},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT03064035","phase":"PHASE4","title":"Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2017-04-05","conditions":"Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)","enrollment":79},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT04718740","phase":"PHASE1","title":"A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-25","conditions":"Recurrent Ovarian Cancer","enrollment":33},{"nctId":"NCT05973188","phase":"PHASE4","title":"Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial","status":"UNKNOWN","sponsor":"Peshawar Institute of Cardiology","startDate":"2023-05-01","conditions":"Left Ventricular Thrombus","enrollment":141},{"nctId":"NCT05085405","phase":"NA","title":"Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-10-11","conditions":"Upper Gastrointestinal Bleeding","enrollment":80},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT05602675","phase":"PHASE1","title":"A Drug Interaction Study of LY3871801 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-02","conditions":"Healthy","enrollment":39},{"nctId":"NCT02206815","phase":"PHASE4","title":"Safety of \"Ticagrelor+ Warfarin\"in Comparison With \"Clopidogrel+Aspirin+Warfarin\"","status":"COMPLETED","sponsor":"Genshan Ma","startDate":"2014-09-19","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":296},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT03894878","phase":"","title":"Association Between Genetic Variant Scores and Warfarin Effect","status":"COMPLETED","sponsor":"Cipherome, Inc.","startDate":"2019-02-11","conditions":"Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus","enrollment":200},{"nctId":"NCT04435769","phase":"","title":"Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-04","conditions":"Atrial Fibrillation","enrollment":109},{"nctId":"NCT02024230","phase":"PHASE4","title":"Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)","status":"COMPLETED","sponsor":"Fujita Health University","startDate":"2014-01","conditions":"Coronary Artery Disease, Atrial Fibrillation, Stroke","enrollment":500},{"nctId":"NCT03178864","phase":"PHASE2","title":"Study of Rivaroxaban for CeREbral Venous Thrombosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-03-12","conditions":"Cerebral Venous Thrombosis","enrollment":55},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT05609500","phase":"","title":"Warfarin Dosage Adjustment Model Analysis Study","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-06","conditions":"Warfarin","enrollment":1200},{"nctId":"NCT03292666","phase":"","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-01-01","conditions":"Venous Thromboembolism, Anticoagulants and Bleeding Disorders","enrollment":39603},{"nctId":"NCT02777047","phase":"NA","title":"Coordination of Oral Anticoagulant Care at Hospital Discharge","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2020-12-16","conditions":"Anticoagulants","enrollment":56},{"nctId":"NCT02688088","phase":"PHASE1","title":"A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03-08","conditions":"Neoplasm Metastasis","enrollment":48},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-08-22","conditions":"Rheumatic Heart Disease","enrollment":4565},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-19","conditions":"Thrombosis","enrollment":192},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100},{"nctId":"NCT05540587","phase":"PHASE2","title":"Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis","status":"RECRUITING","sponsor":"Sung-Hwan Kim","startDate":"2022-05-20","conditions":"Mitral Valve Stenosis, Atrial Fibrillation, Stroke","enrollment":240},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36761,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Warfarin or coumadin","genericName":"Warfarin or coumadin","companyName":"Ottawa Heart Institute Research Corporation","companyId":"ottawa-heart-institute-research-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the regeneration of reduced vitamin K, thereby reducing the formation of blood clots. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}